# Cambridge Cognition wins £1.37m of new eCOA contracts

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-wins-1-37m-of-new-ecoa-contracts/412808985
- Published: 2020-03-17T07:08:27+00:00
- Author: Giles Arbor

**Cambridge Cognition Holdings plc** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
which develops and markets digital solutions to assess brain health, has today announced
that the Company has won a contract for three phase II studies with a new pharmaceutical
client. The Directors believe these studies, which have an aggregate value to the
Company of £1.37 million, demonstrate significant progress for the Company in delivering
its strategy of combining the sale of CANTAB™ cognitive assessments with additional
electronic clinical outcome assessments (eCOA). Contract delivery is expected to
be over a two year period.

The Company will provide the Client with a single vendor solution for all three 
studies, managing the procurement of licences, device provision, CANTABTM cognitive
assessments, a centralised platform for data acquisition and storage, as well as
trial management services. The Client and the Company will additionally collaborate
on the design and testing of a new cognitive task for use in clinics. The contract
also includes the provision of one-to-one training for study sites, as well as the
licensing of eCOA instruments. These additional services, which amount to 44% of
the contract value, will be provided by a subcontractor to Cambridge Cognition.

The three studies will include a total of 180 patients – 60 per clinical group –
with the overall objective being to track early cognitive changes and motor signals
associated with the drug being delivered. By delivering CANTABTM cognitive assessments
and eCOA questionnaires and scales all one platform, the Client will be able to 
sensitively, efficiently and securely monitor three distinct clinical populations.

> **Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:**
> “We are pleased to welcome another pharmaceutical partner to our growing client
> base, using our innovative digital health technologies. This is the second partnership
> that has been secured on the strength of launching our enhanced eCOA solution 
> in 2019; underlining the importance of continuing to invest in developing our 
> digital solutions.”

Share on:
